The facility will meet the enhanced capacity needs for soft gels and will offer an alternate site to Strides’ flagship facility in Bangalore
Photo as seen on Strides company website
Bangalore-based Strides Pharma Science has announced that its step down subsidiary Strides Pharma has acquired a US FDA-approved manufacturing facility in Florida, US from Micelle BioPharma.
US Micelle’s facility is based in Riviera Beach, Florida and is one of the very few manufacturing facilities in the US with a soft gel capsule(SGC) manufacturing suite for formulations with containment needs.
SPI has acquired the manufacturing facility under an asset purchase agreement with Micelle for a consideration of US$0.5 million and will invest up to $10m to build incremental capabilities and add additional dosage formats.
Strides says that the plant is also the only FDA-approved integrated manufacturing-packaging SGC facility in the US. The site has undergone several successful FDA inspections and has no outstanding FDA observations.
With the addition of the Florida site, Strides now has eight formulation sites globally catering to the regulated and emerging markets.